Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3 (Q27851579)
scientific article published on August 23, 2010
Language:
Current Data About Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
(P31) (Q13442814)
(P248)
(P698) 20733134
(P813) Sunday, November 13, 2016

(P50) (Q19283882)
(P1545) 8
(P1932) Gerhard Ehninger

(Q96145785)
(P1545) 5
(P1932) Elihu Estey

(P304) 4339-45

(P407) (Q1860)

(P433) 28

(P478) 28

(P577) Friday, October 1, 2010

Monday, August 23, 2010
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

(P921) (Q181600)

(Q29496)
(P887)

(Q264118)

(Q954625)
(P887)

(P953) https://europepmc.org/articles/pmc4135183?pdf=render
(P2701)
(P6954)
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20733134/?tool=EBI
(P2701)
(P6954)
(P3274)
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20733134/pdf/?tool=EBI
(P2701)
(P6954)
(P3274)
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

http://intl.jco.org/cgi/content/abstract/28/28/4339
(P6954)
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

https://europepmc.org/articles/PMC4135183
(P2701)
(P6954)
(P3274)
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

https://europepmc.org/articles/PMC4135183?pdf=render
(P2701)
(P6954)
(P3274)
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

https://doi.org/10.1200/jco.2010.28.9678
(P6954)
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.28.9678
(P248)
(P356) 10.1200/JCO.2010.28.9678
(P854) https://api.crossref.org/works/10.1200/JCO.2010.28.9678
(P813) Friday, June 21, 2024

(P1433) (Q400292)

(P1476) "Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3" (language: en)
(P248)
(P356) 10.1200/JCO.2010.28.9678
(P854) https://api.crossref.org/works/10.1200/JCO.2010.28.9678
(P813) Friday, June 21, 2024

(P2093) Thomas Fischer
(P1545) 1

Ilene Galinsky
(P1545) 4

Carlo Lanza
(P1545) 6

Edward Fox
(P1545) 7

Catherine Dutreix
(P1545) 14

Alice Huntsman-Labed
(P1545) 15

Jodi Virkus
(P1545) 16

Richard M. Stone
(P1545) 2
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

Daniel J. Deangelo
(P1545) 3
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

Eric J. Feldman
(P1545) 9
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

Gary J. Schiller
(P1545) 10
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

Virginia M. Klimek
(P1545) 11
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

Stephen D. Nimer
(P1545) 12
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

D. Gary Gilliland
(P1545) 13
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

Francis J. Giles
(P1545) 17
(P248)
(P698) 20733134
(P854) https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20733134
(P813) Friday, June 21, 2024

(P2860) (Q33680292)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q39981715)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q40252880)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q40390558)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q40559231)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q40543180)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q35594041)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q35018629)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q34139532)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q34664542)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q40760923)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q32073544)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q40737646)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q34746103)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Friday, September 29, 2017

(Q45929224)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Saturday, June 2, 2018

(Q46233590)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Saturday, June 2, 2018

(Q45040849)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Saturday, June 2, 2018

(Q45042550)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Tuesday, November 27, 2018

(Q44298388)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Tuesday, November 27, 2018

(Q44068434)
(P248)
(P854) https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4135183
(P813) Tuesday, November 27, 2018

(Q80794418)
(P248)
(P854) https://pubmed.ncbi.nlm.nih.gov/20733134
(P813) Saturday, December 12, 2020
(P887)

other details
aliases Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
description scientific article published on August 23, 2010

External Links
(P356) 10.1200/JCO.2010.28.9678
(P698) 20733134
(P932) 4135183
(P3181) 2213766